A study of Vertex’s potentially ground-breaking cell therapy VX-880 for type 1 diabetes has been put on hold by the US Food and Drug Administration, catching the company by surprise, as it unveiled what it called 'landmark' efficacy data.
Vertex’s stem cell-derived therapy replaces the islet cells missing in people with the condition, with the hope of providing a cure for type 1 diabetes by restoring insulin
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?